Investigator Richard Adams of Cardiff University discusses the failure of Erbitux to show survival benefits in the COIN clinical trial presented at the ECCO-ESMO congress in Berlin.
Ben Hirschler
Ben Hirschler’s Profile
TrackbackPost Your Comment
House Rules:
- We moderate all comments and will publish everything that advances the post directly or with relevant tangential
- We try not to publish comments that we think are offensive or appear to pass you off as another person, and we will be conservative if comments may be considered libelous.information.
